Dynegy Aktie
WKN DE: A1J5JU / ISIN: US26817R1086
21.01.2025 14:20:48
|
Dyne's Myotonic Secures FDA's Fast Track Designation For Myotonic Dystrophy Type 1 Therapy
(RTTNews) - Dyne Therapeutics, Inc. (DYN), Tuesday announced that the U.S. Food and Drug Administration has granted Fast Track designation for DYNE-101 for the treatment of myotonic dystrophy type 1, a rare, progressive, genetic disease.
The Fast Track designation is based on clinical data from the company's ongoing Phase 1/2 ACHIEVE trial, demonstrating substantial functional benefits and splicing correction in participants.
The clinical-stage neuromuscular disease company intends to submit for U.S. Accelerated Approval in the first half of 2026.
In the pre-market hours, Dyne's stock is trading at $14.01, down 0.82 percent on the Nasdaq.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Dynegy Incmehr Nachrichten
Keine Nachrichten verfügbar. |